Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

The Medical Device Co. That’s on the Cutting-Edge of Advancing Heart Disease Treatment

Back in early September , we introduced our Stockhouse audience to a unique play in the emerging medical tech space – Neovasc Inc. ( TSX: NVCN , OTCQB: NVCN , Forum ). The company develops, manufactures, and markets products for the rapidly growing cardiovascular marke...
Dave Jackson | November 29, 2021 |

BASF and Cardiol Therapeutics recommended buys; TUI rides momentum

BASF (OTCQX:BASFY) shares have gained over 30% within six months. But is the rally in BASF shares slowly running out of steam? The fact that the stock did not rise sharply yesterday despite a significant price target increase suggests this is the case. Many experts see ...
Fabian Lorenz | April 10, 2024 |

Ra Pharmaceuticals Shares Up 100% Following $2.1 Billion Takeover Bid

Shares of Ra Pharmaceuticals doubled today after the firm announced that it will be acquired by Belgian firm UCB for $48 per share in an all cash deal. Prior to the market open this morning Ra Pharmaceuticals Inc. (RARX:NASDAQ) and Brussels-based UCB (UCB:Euronext)...
Streetwise Reports | October 11, 2019 |

Buzz on the Bullboards: ‘Tis the Season for a Rebound?

Once the American Thanksgiving passes, the mood in North American markets seems to shift dramatically as investors contend with holidays, gifts, and vacations on one hand, with the end of their fiscal years on the other. Companies also look to end the calendar year on...
Stockhouse Editorial | December 1, 2021 |

Buzz on the Bullboards: Good stocks with bad publicity

It was hedge fund legend Ray Dalio who said: “He who lives by the crystal ball will eat shattered glass.” Many stock markets may have seen a higher start to the year so far, but there is far from a universal sentiment across the sectors, with s...
Jonathon Brown | January 25, 2024 |

Buzz on the Bullboards: Crisis Creates Opportunity

As November draws to a close, many investors may take time to consider what they are thankful for. Even if the American Thanksgiving isn’t something you celebrate, there are a lot of reasons to be thankful these days, from having our health, to major stock...
Stockhouse Editorial | November 25, 2020 |

Buzz on the Bullboards: A Big Picture Look at Small-Cap Opportunities

(Image via BlackBerry Limited.) When the going gets tough, where do small-cap investors go? Strong earnings growth and the increasing likelihood of additional US fiscal stimulus last week pushed Wall Street stocks toward fresh record highs. While activity moved ...
Stockhouse Editorial | February 17, 2021 |

Theralase is raising up to $5.3M to complete bladder cancer study

Theralase Technologies is announcing a brokered financing raise for up to C$5.3 million Proceeds of the financing will be used to further the Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study Ruvidar is designed to destroy solid core tum...
Coreena Robertson | November 6, 2023 |

Neovasc Shares Climb 80% Upon FDA Premarket Approval Filing for Refractory Angina Device

Shares of specialty cardiovascular medical device company Neovasc Inc. opened more than 100% higher after the firm reported that it submitted a Premarket Approval application to the FDA for its Neovasc Reducer device for use in the treatment of refractory angina. This...
Streetwise Reports | January 3, 2020 |

MyoKardia Shares Get a Jolt from Positive Phase 3 HCM Clinical Trial Results

Shares of MyoKardia traded 60% higher, setting a new 52-week high price, after the company reported that it met all primary and secondary endpoints in the Phase 3 EXPLORER study of mavacamten in treatment of obstructive hypertrophic cardiomyopathy. Clinical-...
Streetwise Reports | May 12, 2020 |
1 2 3 4 5 6 7 8 9 10 ...